Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News UNITY Biotechnology Inc UBX

Healthcare Biotechnology
UNITY Biotechnology, Inc. is a biotechnology company engaged in researching and developing therapeutics to slow, halt or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms... see more

Recent & Breaking News (NDAQ:UBX)

UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease

GlobeNewswire February 14, 2022

UNITY Biotechnology Announces Restructuring to Advance Corporate Strategy and Focus on Key Ophthalmology Programs

GlobeNewswire February 3, 2022

UNITY Biotechnology Reports Granting of New Employment Inducement Award

GlobeNewswire February 2, 2022

UNITY Biotechnology Provides Program Updates and Anticipated Milestones for 2022

GlobeNewswire January 4, 2022

UNITY Biotechnology Reports Granting of New Employment Inducement Award

GlobeNewswire December 22, 2021

UNITY Biotechnology Announces Exclusive License Agreement with Jocasta Neuroscience to Continue Development of α-Klotho Program

GlobeNewswire December 20, 2021

UNITY Biotechnology, Inc. Reports Third Quarter 2021 Financial Results and Business Updates

GlobeNewswire November 10, 2021

UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye Disease

GlobeNewswire November 9, 2021

UNITY Biotechnology Reports Granting of New Employment Inducement Awards

GlobeNewswire November 3, 2021

UNITY Biotechnology Reports Granting of New Employment Inducement Awards

GlobeNewswire October 6, 2021

UNITY Biotechnology Announces Positive 12-Week Data from Phase 1 Clinical Trial of UBX1325 in Advanced Vascular Eye Disease

GlobeNewswire October 5, 2021

UNITY Biotechnology, Inc. to Participate in Upcoming Investor Conferences

GlobeNewswire September 7, 2021

UNITY Biotechnology Reports Granting of New Employment Inducement Awards

GlobeNewswire August 18, 2021

UNITY Biotechnology, Inc. to Participate in the H.C. Wainwright Ophthalmology Virtual Conference

GlobeNewswire August 16, 2021

UNITY Biotechnology, Inc. Reports Second Quarter 2021 Financial Results and Business Updates

GlobeNewswire August 10, 2021

Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325

PR Newswire July 28, 2021

UNITY Biotechnology Reports Granting of New Employment Inducement Awards

GlobeNewswire July 28, 2021

UNITY Biotechnology to Host Investor Call with Retinal Expert Robert Bhisitkul, M.D., Ph.D., to Discuss Recent Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease

GlobeNewswire July 23, 2021

UNITY Biotechnology Announces Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease

GlobeNewswire July 6, 2021

UNITY Biotechnology Reports Granting of New Employment Inducement Awards

GlobeNewswire June 2, 2021